Andrew Murphy

Andrew Murphy is the Sr. Vice President, Early Research at Kriya Therapeutics. Dr. Murphy joined Kriya from Kitty Hawk Biosciences where he developed in vitro assays to support client gene therapy programs. He has over fifteen years of experience in biopharmaceutical research and development from discovery to early clinical evaluation. While at Liquidia technologies, Dr. Murphy led teams developing nucleic acid and protein adjuvant vaccines. Murphy has also held positions of increasing responsibility at KBI Biopharma, Duke University, and Proteovec.

Dr. Murphy received his PhD in chemistry from Stanford University and his undergraduate degree in chemistry from Oberlin College.